ライフサイエンスコーパス: CoQ10

1 used for the determination of coenzyme Q10 (CoQ10).

2 the synthesis of ubiquinone or coenzyme Q10 (CoQ10).

3 SA-ST) was used to encapsulate coenzyme Q10 (CoQ10).

4 atin treatment reduces circulating levels of CoQ10.

5 s of O-2 generation than those obtained with CoQ10.

6 tion between SMPs reconstituted with CoQ9 or CoQ10.

7 and pork breakfast sausages, fortified with CoQ10.

8 plements, and substantial recent exposure to CoQ10.

9 in CoQ10 biosynthesis may be treatable with CoQ10.

10 e found to be more stable in the presence of CoQ10.

11 f age, which was significantly attenuated by CoQ10.

12 caspase-2 activation, which is regulated by CoQ10.

13 emulsions was compared to emulsions without CoQ10.

14 tandard feed pellets with or without dietary CoQ10 (1 mg/kg body weight per day) supplementation.

15 er standard diet or a diet supplemented with CoQ10 (200 mg/kg/day) for five weeks.

16 Liquid CoQ10 250 mg followed by 150 mg TID for 5 days or placeb

17 n decreased migration, which was reversed by CoQ10 addition.

18 olled clinical trials of monopreparations of CoQ10 administered orally to cancer patients were includ

19 ated whether combining mild hypothermia with CoQ10 after out-of-hospital cardiac arrest provides addi

20 placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received 1200 IU/d of vitamin E.

21 Coenzyme Q10 (CoQ10), an antioxidant and mitochondrial cofactor, has s

22 Coenzyme Q10 (CoQ10), an antioxidant that supports mitochondrial funct

23 ong-term (6 mo) treatment with coenzyme Q10 (CoQ10), an endogenous antioxidant.

24 systemic administration of the water-soluble CoQ10 analog reduced oxidative-induced cochlear damage,

25 ntly (62%) greater in the group treated with CoQ10 and MPTP than in the group treated with MPTP alone

26 antly higher (37%) in the group treated with CoQ10 and MPTP than in the group treated with MPTP alone

27 affected subjects showed reduced amounts of CoQ10 and often displayed a decrease in CoQ10-dependent

28 tive saposin B (sapB) has been shown to bind CoQ10 and subsequently be excreted.

29 sted by incorporating either reduced CoQ9 or CoQ10 and the lipophylic azoinitiator 2,2'-azobis(2,4-di

30 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 participants (29 who received placebo, 19

31 ceived placebo, 19 who received 1200 mg/d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew

32 4 received placebo, 87 received 1200 mg/d of CoQ10, and 86 received 2400 mg/d of CoQ10), and 65 parti

33 he calibration graph was 0.03-0.50mumolL(-1) CoQ10, and the detection limit was 0.008mumolL(-1).

34 nes or coenzyme Q (CoQ) homologues, CoQ9 and CoQ10, are related with the rate of O-2 generation was t

35 CoQ10 at 2,700 mg daily for 9 months shows insufficient

36 es showed no significant differences between CoQ10 at 2,700 mg/day and placebo.

37 chromatography) resin and successfully bound CoQ10 at pH 5.0 with release of the CoQ10 at pH 9.0.

38 ly bound CoQ10 at pH 5.0 with release of the CoQ10 at pH 9.0.

39 in ADCK4 or other genes that participate in CoQ10 biosynthesis may be treatable with CoQ10.

40 ocytes, ADCK4 interacted with members of the CoQ10 biosynthesis pathway, including COQ6, which has be

41 ects in three of the nine genes required for CoQ10 biosynthesis, all of which are associated with ear

42 several genes encoding proteins involved in CoQ10 biosynthesis.

43 We focused on the coenzyme Q10 (CoQ10) biosynthesis gene Coq2, the silencing of which di

44 s been shown to participate in coenzyme Q10 (CoQ10) biosynthesis.

45 eteromeric complex that contains most of the CoQ10 biosynthetic enzymes.

46 entation can raise the circulating levels of CoQ10, but data on the effect of CoQ10 supplementation o

47 The extracts were analyzed for CoQ10 by high-performance liquid chromatography (HPLC).

48 Quantification of CoQ10 by HPLC showed that the retention of this lipophil

49 Our results indicate that CoQ10 can attenuate the MPTP-induced loss of striatal do

50 Consequently, CoQ10 can be tested in patients requiring statin treatme

51 tigations are necessary to determine whether CoQ10 can improve the tolerability of cancer treatments.

52 strated that by blocking caspase-2 activity, CoQ10 can protect the cells from mitochondrial membrane

53 The routine use of CoQ10 cannot be recommended in statin-treated patients.

54 heart SMPs with different amounts of CoQ9 or CoQ10 caused an initial increase in the rates of O-2 gen

55 subsequent introduction of Triton X-100 and CoQ10 causes the MLs lysis and the cresyl violet oxidati

56 The retention rate of CoQ10, composition and cheese yield were also determined

57 supplementation increased (P < 0.01) hepatic CoQ10 concentrations and ameliorated liver fibrosis (P <

58 Furthermore, cochlear levels of CoQ9 and CoQ10 content increased.

59 y CoQ9 and cow heart SMPs, with high natural CoQ10 content, were chosen for depletion/reconstitution

60 ought that this interaction between sapB and CoQ10 could be a mechanism to avoid any possible CoQ10 t

61 in a cheese matrix, hence demonstrating that CoQ10 could be used in the development of functional che

62 whether oral administration of coenzyme Q10 (CoQ10) could attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahy

63 0 supplements in diseases other than primary CoQ10 deficiencies is insufficient.

64 s is recognized in the rare cases of primary CoQ10 deficiencies, a potential role for CoQ10 supplemen

65 Primary coenzyme Q10 (CoQ10) deficiencies are rare, clinically heterogeneous d

66 Significant CoQ10 deficiency and reduced MRC enzyme activities in th

67 CoQ10 deficiency has been identified in fibroblasts and

68 ient evidence to prove the etiologic role of CoQ10 deficiency in statin-associated myopathy and that

69 Awareness of CoQ10 deficiency is important because individuals with p

70 prompted the hypothesis that statin-induced CoQ10 deficiency is involved in the pathogenesis of stat

71 s clinical presentations and associated with CoQ10 deficiency.

72 CK3) is one of several genes associated with CoQ10 deficiency.

73 performed sequencing of known Coenzyme Q10 (CoQ10) deficiency genes in 22 patients with unexplained

74 Ubiquinone (CoQ10) deficiency is one of the potentially treatable ca

75 in 1989, our understanding of coenzyme Q10 (CoQ10) deficiency is only now coming of age with the rec

76 s of CoQ10 and often displayed a decrease in CoQ10-dependent ETC complex activities.

77 lection, 35 participants per group) compared CoQ10 doses of 1,800 and 2,700 mg/day.

78 There are no known negative side effects of CoQ10 even at very high levels.

79 CoQ9 and inversely related to the amount of CoQ10, extractable from their cardiac mitochondria.

80 ims were to choose between two high doses of CoQ10 for ALS, and to determine if it merits testing in

81 The use of CoQ10 fortification in the production of a functional fo

82 urs after CPR was significantly lower in the CoQ10 group (0.47 versus 3.5 ng/mL).

83 Three-month survival in the CoQ10 group was 68% (17 of 25) and 29% (7 of 24) in the

84 For the first time, CoQ10 has been encapsulated in a cheese matrix, hence de

85 The use of coenzyme Q10 (CoQ10) has been increasing rapidly during recent years d

86 Coenzyme Q10 (CoQ10) has shown a protective effect in neurodegenerativ

87 demonstrate that recombinant sapB will bind CoQ10 in a pH-dependent manner similar to sapB binding w

88 This fact, plus the role of CoQ10 in mitochondrial energy production, has prompted t

89 us trials during the past 30 years examining CoQ10 in patients with HF have been limited by small num

90 aimed to determine the bio-accessibility of CoQ10 in processed meat products, beef patties and pork

91 (-1) and was applied to the determination of CoQ10 in several food samples.

92 The average concentrations of CoQ10 in the choroid was 27+/-16 nanomoles/g dry choroid

93 The cooking retention level of CoQ10 in the products was found to be 74+/-1.42% for pat

94 The average concentration of CoQ10 in the retina was 42+/-11 nanomoles/g dry retina f

95 CoQ10 is a highly lipophilic molecule with a chemical st

96 CoQ10 is an essential component of the electron transpor

97 of statin therapy on intramuscular levels of CoQ10 is not clear, and data on intramuscular CoQ10 leve

98 The interaction between sapB and CoQ10 is poorly understood.

99 Current literature suggests that CoQ10 is relatively safe with few drug interactions and

100 Mutations in ADCK4 resulted in reduced CoQ10 levels and reduced mitochondrial respiratory enzym

101 oQ10 is not clear, and data on intramuscular CoQ10 levels in symptomatic patients with statin-associa

102 CoQ10 levels in the retina can decline by approximately

103 guage articles relating statin treatment and CoQ10 levels via a PubMed search through August 2006.

104 he relationship between statin treatment and CoQ10 levels were examined in detail.

105 minergic axons in aged mice and suggest that CoQ10 may be useful in the treatment of Parkinson's dise

106 long-term administration of the antioxidant CoQ10 may represent a promising therapeutic strategy for

107 Coenzyme Q10 (CoQ10) may represent a safe therapeutic option for patie

108 Suggestions that CoQ10 might reduce the toxicity of cancer treatments hav

109 The effect of CoQ10 on the physico-chemical stability of emulsions was

110 port the important role of the coenzyme Q10 (CoQ10) on the activity of caspase-2 upstream of mitochon

111 randomly assigned to either hypothermia plus CoQ10 or hypothermia plus placebo after CPR.

112 ly assigned to receive placebo, 1200 mg/d of CoQ10, or 2400 mg/d of CoQ10; all participants received

113 ve to placebo), and 8.0 points (2400 mg/d of CoQ10; P = .21 relative to placebo).

114 9 points (placebo), 7.5 points (1200 mg/d of CoQ10; P = .49 relative to placebo), and 8.0 points (240

115 Nine CoQ10 patients versus 5 placebo patients survived with a

116 that controls ROS formation independently of CoQ10, phenocopied the effect of Coq2-RNAi.

117 digestion and HPLC analysis to quantify the CoQ10 present in fortified products (100mg/g).

118 The pretreatment of CoQ10 prevented EtOH-induced caspase-2 activation and mi

119 Incorporation of CoQ10 provided protection from adriamycin-induced mitoch

120 The results suggested that CoQ10 provides some protection against cardiotoxicity or

121 and levels of coenzymes Q9 and Q10 (CoQ9 and CoQ10, respectively) as indicators of endogenous antioxi

122 ntaining homologs of CoQ, including CoQ9 and CoQ10, resulted in the essentially complete reduction of

123 CoQ10 retention of the emulsion and freeze dried product

124 ng a common component of cellular membranes, CoQ10's most prominent role is to facilitate the product

125 -I and Co-II shifts O*2- generation from the CoQ10 sites to more proximal sites, such as flavines, an

126 erate improvement of the fraction of reduced CoQ10, suggesting limited efficacy of NAC monotherapy.

127 in major adverse cardiovascular events with CoQ10 supplementation in a contemporary HF population.

128 tely powered randomized controlled trials of CoQ10 supplementation in patients with HF.

129 anisms, clinical data, and safety profile of CoQ10 supplementation in patients with HF.

130 his study has renewed interest in evaluating CoQ10 supplementation in patients with HF.

131 CoQ10 supplementation increased (P < 0.01) hepatic CoQ10

132 g levels of CoQ10, but data on the effect of CoQ10 supplementation on myopathic symptoms are scarce a

133 CoQ10 supplementation prevented liver fibrosis accompani

134 CoQ10 supplementation was initiated following these gene

135 or secondary variants may benefit from oral CoQ10 supplementation.

136 causes of ARCAs as some patients respond to CoQ10 supplementation.

137 ard diet and one group that had received the CoQ10 supplemented diet were treated with MPTP.

138 ary CoQ10 deficiencies, a potential role for CoQ10 supplements in cardiovascular disease, particularl

139 Current evidence for a benefit of CoQ10 supplements in diseases other than primary CoQ10 d

140 While the therapeutic utility of CoQ10 supplements is recognized in the rare cases of pri

141 Restoration of CoQ10 synthesis by vanillic acid partially rescued the p

142 s were fortified with a micellarized form of CoQ10 to enhance solubility to a concentration of 1mg/g

143 for oral supplementation with coenzyme Q10 (CoQ10) to improve the tolerability of cancer treatments.

144 0 could be a mechanism to avoid any possible CoQ10 toxicity.

145 ally completely absent after the 6-mo, daily CoQ10 treatment in db(-)/db(-) mice when started at 7 wk

146 ift mutation had partial remission following CoQ10 treatment.

147 and this effect was also blocked by the 6-mo CoQ10 treatment.

148 CoQ10 was dissolved in rice bran oil and incorporated in

149 The emulsion with CoQ10 was used as a functional cream in the cheese makin

150 Coenzyme Q10 (CoQ10) was encapsulated successfully in a nutraceutical

151 verse effects of alcohol while coenzyme Q10 (CoQ10) was not very effective against alcohol insults.

152 Respiratory-chain enzyme activities and CoQ10 were decreased in severely affected patients but r

153 Manufacturers of CoQ10 were identified and contacted.

154 e similar in both groups; no side effects of CoQ10 were identified.

155 Combining CoQ10 with mild hypothermia immediately after CPR appear

156 d of CoQ10, and 17 who received 2400 mg/d of CoQ10) withdrew prematurely.

157 mentation with the antioxidant coenzyme Q10 (CoQ10) would prevent this programmed phenotype.